نتائج البحث

The potential of deferasirox as a novel therapeutic modality in gastric cancer.

• Authors : Jung Hye Choi¹ ; Jung Soon Kim¹; Young Woong Won¹

• Source: World Journal of Surgical Oncology. 3/10/2016, Vol. 14, p1-7. 7p.

تفاصيل العنوان

Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study.

• Authors : Tartaglione, Immacolata¹ (AUTHOR); Origa, Raffaella² (AUTHOR); Kattamis, Antonis³ (AUTHOR)

• Source: Experimental Hematology & Oncology. 8/10/2020, Vol. 9 Issue 1, p1-11. 11p.

تفاصيل العنوان

Retraction Note: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.

• Authors : Amano S; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.; Kaino S

• Source: BMC cancer [BMC Cancer] 2023 Dec 11; Vol. 23 (1), pp. 1218. Date of Electronic Publication: 2023 Dec 11.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.

• Authors : Amano S; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.; Kaino S

Subjects: Cell Movement/Cell Movement/Cell Movement/*drug effects ; Deferasirox/Deferasirox/Deferasirox/*pharmacology ; Iron Chelating Agents/Iron Chelating Agents/Iron Chelating Agents/*pharmacology

• Source: BMC cancer [BMC Cancer] 2020 Jul 22; Vol. 20 (1), pp. 681. Date of Electronic Publication: 2020 Jul 22.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.

• Authors : Amano S; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.; Kaino S

• Source: BMC cancer [BMC Cancer] 2023 Jun 23; Vol. 23 (1), pp. 582. Date of Electronic Publication: 2023 Jun 23.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.

• Authors : Tataranni T; Laboratory of Pre-Clinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, PZ, Italy.; Mazzoccoli C

Subjects: Deferasirox/Deferasirox/Deferasirox/*pharmacology ; Hematopoietic Stem Cells/Hematopoietic Stem Cells/Hematopoietic Stem Cells/*drug effects ; Hematopoietic Stem Cells/Hematopoietic Stem Cells/Hematopoietic Stem Cells/*metabolism

• Source: Stem cell research & therapy [Stem Cell Res Ther] 2019 Jun 13; Vol. 10 (1), pp. 171. Date of Electronic Publication: 2019 Jun 13.Publisher: BioMed Central Country of Publication: England NLM ID: 101527581 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.

• Authors : Hirofumi Harima¹; Seiji Kaino¹ ; Taro Takami¹

• Source: BMC Cancer. 8/31/2016, Vol. 16, p1-11. 11p. 1 Diagram, 2 Charts, 6 Graphs.

تفاصيل العنوان

Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.

• Authors : Harima H; Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami-Kogushi, Ube, Yamaguchi, 755-8505, Japan.; Kaino S

Subjects: Antineoplastic Agents/Antineoplastic Agents/Antineoplastic Agents/*pharmacology ; Apoptosis/Apoptosis/Apoptosis/*drug effects ; Benzoates/Benzoates/Benzoates/*pharmacology

• Source: BMC cancer [BMC Cancer] 2016 Aug 31; Vol. 16, pp. 702. Date of Electronic Publication: 2016 Aug 31.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

The potential of deferasirox as a novel therapeutic modality in gastric cancer.

• Authors : Choi JH; Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri-si, Gyeonggi-do, 471-701, Republic of Korea. .; Kim JS

Subjects: Apoptosis/Apoptosis/Apoptosis/*drug effects ; Benzoates/Benzoates/Benzoates/*pharmacology ; Cell Cycle/Cell Cycle/Cell Cycle/*drug effects

• Source: World journal of surgical oncology [World J Surg Oncol] 2016 Mar 10; Vol. 14, pp. 77. Date of Electronic Publication: 2016 Mar 10.Publisher: BioMed Central Country of Publication: England NLM ID: 101170544 Publication Model: Electronic Cited Medium:

تفاصيل العنوان

Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells.

• Authors : Legendre C; INSERM U1066, Micro et Nanomédecines Biomimétiques, IBS - CHU, 4 Rue Larrey, F-49933, Angers, France.; Avril S

Subjects: Cell Hypoxia*; Benzoates/Benzoates/Benzoates/*administration & dosage ; Glioblastoma/Glioblastoma/Glioblastoma/*metabolism

• Source: BMC cancer [BMC Cancer] 2016 Feb 01; Vol. 16, pp. 51. Date of Electronic Publication: 2016 Feb 01.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium:

تفاصيل العنوان